ICVX - AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M | Benzinga
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.
The deal provides AstraZeneca access to experimental vaccines targeting common respiratory disease-causing viruses.
The upfront cash portion of the consideration represents an equity value of approximately $838 million, nearly a 43% premium over Icosavax’s share price of $10.49 on Monday. The acquisition is expected to